Twice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy

AIDS

Volumn 25, Issue 9, 2011, Pages 1179-1187

  Murphy, Alison A ^a   Herrmann, Eva ^b   Osinusi, Anu O ^a,d   Wu, Lynn ^c   Sachau, William ^a   Lempicki, Richard A ^d   Yang, Jun ^d   Chung, Tei L ^b   Wood, Brad J ^e   Haagmans, Bart L ^f   Kottilil, Shyam ^a   Polis, Michael A ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b GOETHE UNIVERSITY   (Germany)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d SAIC FREDERICK INC   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

hepatitis C virus; HIV; sustained virologic response; twice weekly interferon; viral kinetics

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; INTERFERON STIMULATED GENE FACTOR; LIVER ENZYME; NUCLEIC ACID BINDING PROTEIN; PEGINTERFERON ALPHA2A; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; AFRICAN AMERICAN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; DISTRIBUTION VOLUME; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; GENE EXPRESSION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MENTAL DISEASE; MIXED INFECTION; MORNING DOSAGE; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; VIRAL CLEARANCE;

EID: 85027943745     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283471d53     Document Type: Article

References (31)

1. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34:831-837. (Pubitemid 34194855)
2. Jain MK, Skiest DJ, Cloud JW, Jain CL, Burns D, Berggren RE. Changes in mortality related to human immunodeficiency virus infection: comparative analysis of inpatient deaths in 1995 and in 1999-2000. Clin Infect Dis 2003; 36:1030-1038. (Pubitemid 36513289)
3. Selik RM, Byers RH Jr, Dworkin MS. Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr 2002; 29:378-387. (Pubitemid 34288892)
4. Martinez-Sierra C, Arizcorreta A, Diaz F, Roldan R, Martin- Herrera L, Perez-Guzman E, et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 2003; 36:491-498. (Pubitemid 36241318)
5. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30:1054-1058. (Pubitemid 29458296)
6. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292:2839-2848. (Pubitemid 39628231)
7. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIVcoinfected persons. N Engl J Med 2004; 351:451-459. (Pubitemid 38988594)
8. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
9. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965. (Pubitemid 32913521)
10. Perez-Olmeda M, Nunez M, Romero M, Gonzalez J, Castro A, Arribas JR, et al. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003; 17:1023-1028. (Pubitemid 36549714)
11. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez- Garcia J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-450. (Pubitemid 38988593)
12. Rozenberg L, Haagmans BL, Neumann AU, Chen G, McLaughlin M, Levy-Drummer RS, et al. Therapeutic response to peg- IFN-alpha-2b and ribavirin in HIV/HCV co-infected African- American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics. AIDS 2009; 23:2439-2450.
13. Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley- Lucas TE, Afdhal N, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131:470-477. (Pubitemid 44142464)
14. Neumann A, Polis M, Rozenberg L, Jackson J, Reitano K, McLaughlin M, et al. Differential antiviral effect of PEG-interferon- alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients. AIDS 2007; 21:1855-1865. (Pubitemid 47329762)
15. Torriani FJ, Ribeiro RM, Gilbert TL, Schrenk UM, Clauson M, Pacheco DM, et al. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. J Infect Dis 2003; 188:1498-1507. (Pubitemid 37523935)
16. Talal AH, Shata MT, Markatou M, Dorante G, Chadburn A, Koch R, et al. Virus dynamics and immune responses during treatment in patients coinfected with hepatitis C and HIV. J Acquir Immune Defic Syndr 2004; 35:103-113. (Pubitemid 38133731)
17. Talal AH, Ribeiro RM, Powers KA, Grace M, Cullen C, Hussain M, et al. Pharmacodynamics of PEG-IFNa differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Hepatology 2006; 43:943-953. (Pubitemid 43724619)
18. Roberts SK, Weltman MD, Crawford DH, McCaughan GW, Sievert W, Cheng WS, et al. Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. Hepatology 2009; 50:1045-1055.
19. Bjoro K,Bell H,HellumKB, SkaugK,RaknerudN, Sandvei P, et al. Effect of combined interferon-alpha induction therapy and ribavirin on chronic hepatitis C virus infection: a randomized multicentre study. Scand J Gastroenterol 2002; 37:226-232. (Pubitemid 34102261)
20. Layden TJ, Layden JE, Reddy KR, Levy-Drummer RS, Poulakos J, Neumann AU. Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C. J Viral Hepat 2002; 9:334-339.
21. Lutchman G, Hoofnagle JH. Viral kinetics in hepatitis C. Hepatology 2003; 37:1257-1259. (Pubitemid 36667303)
22. Kottilil S, Yan MY, Reitano KN, Zhang X, Lempicki R, Roby G, et al. Human immunodeficiency virus and hepatitis C infections induce distinct immunologic imprints in peripheral mononuclear cells. Hepatology 2009; 50:34-45.
23. Shudo E, Ribeiro RM, Perelson AS. Modeling hepatitis C virus kinetics under therapy using pharmacokinetic and pharmacodynamic information [review]. Expert Opin Drug Metab Toxicol 2009; 5:321-332.
24. Dahari H, Ribeiro RM, Perelson AS. Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology 2007; 46:16-21. (Pubitemid 47171916)
25. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003; 37:1351-1358. (Pubitemid 36667315)
26. Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004; 432:922-924. (Pubitemid 40037156)
27. Lempicki RA, Polis MA, Yang J, McLaughlin M, Koratich C, Huang DW, et al. Gene expression profiles in hepatitis C virus (HCV) and HIV coinfection: class prediction analyses before treatment predict the outcome of anti-HCV therapy among HIV-coinfected persons. J Infect Dis 2006; 193:1172-1177.
28. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL Jr, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa- 2a (40 KD)/ribavirin. J Hepatol 2005; 43:425-433. (Pubitemid 41111423)
29. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361:580-593.
30. Katsounas A, Frank AC, Yang J, Lempicki RA, Neumann AU, Polis MA, Kottilil S. Differential specificity of innate host gene expression on interferon-mediated antiviral effect on HCV and HIV. Hepatology 2009; 50 (Suppl 4):600A-705A; abstract 797.
31. Lempicki RA, Yang J, Masur H, Polis MA, Kottilil S. Exhaustion of type I interferon signaling pathway as a major mechanism for lack of response to Peg-interferon and ribavirin therapy in HIV/HCV co-infected subjects. Hepatology 2009; 50 (Suppl 4): 600A-705A; abstract 804.